Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 3, 2008, Pages 299-306

  Khan, Muhammad Khalid ^a   Khan, Muhammad Farid ^a  

^a GOMAL UNIVERSITY   (Pakistan)

Author keywords

Area under the curve; Ciprofloxacin two different formulations; Peak plasma level; Time at which maximum concentration of drug

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL EVALUATION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; REFERENCE VALUE; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CROSS-OVER STUDIES; HUMANS; MALE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 55249088378     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aliabadi FS and Lees P (1997). Pharmacodynamic and Pharmacokinetic inter relationship of antibacterial drugs. Vet. Pharmacol. Ther., 20(Suppl 1): 14-17.
2. Anadon A, Maninez-Larranaga MR, Diaz J, Bringas P, Martmez MA, Pernandez-cruz ML, Pernandez MC and Pernandez R (1995). Pharmacokinetics and residues of enrofloxacin in chickens. Am. J. Vet. Res., 56: 501-506.
3. Arret B, Johnson OP and Kirshbaum A (1971). Outline of details for microbiological assays of antibiotics, second revision. J. Pharm. Sci., 60: 1689-1694.
4. th Ed.. Iowa State University Press Ames, pp.829-830.
5. Bottner A, Schmid P and Hume R (1995). In vitro efficacy of cefquinone (INN) and other anti-infective drugs against bovine bacterial isolates from Belgium, France, Germany, The Netherlands, and the United Kingdom. J. Vet. Med. B. 42: 377-383.
6. Brown SA (1996). Fluoroquinolones in animal Health. J. Vet. Pharmacol. Therap., 19: 1-14.
7. Catchpole C, Andrews JM, Woodcock J and Wise R (1994). The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J. Antimicrob. Chemother., 33(1): 103-110. (Pubitemid 24043845)
8. Definitions, Bioavailability and Bioequivalence Requirements, FDA'S Regulation (1991). Title 21 The code of Federal Regulation under CFR. Part 320.1
9. Dowling PM, Wilson RC, Tyler JW and Duran SH (1995). Pharmacokinetics of Ciprofloxacin in ponies. J. Vet. Pharmacol. Therap., 18: 7-12.
10. Drusano GL, Johnson DE, Rosen M and Standiford HC (1993). Pharmacodynamics of a fluoroquinolones antimicrobial agent in a neutropenic rat model of Pesudomonas sepsis. Antimicrob. Agents Chemotherap., 37: 448-490. (Pubitemid 23072592)
11. Escobar Y and Hoyo-Vaditlo C (2003). Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. Arzneimittelforschung, 53(9): 664-667. (Pubitemid 37159595)
12. Garcia Ovando H, Errecalde C, Prieto G, Luders C, Puelles I, Berccochea C and Fernandez W (1996). Pharmacokinetics of enrofloxacin in calves. Archievos de Medicina Veterinaria, 28: 107-111.
13. Garrelts JC, Jost G, Kowalsky SF, Krol GJ and Lettieri JT (1996). Ciprofloxacin Pharmacokinetics- in burn patients. Antimicrob. Agents Chemother., 40(5): 1153-1156.
14. Hu C, Kneusei R and Barnas G (2003). Online Calculator. http://www.int med.mcw.edu/clinicalc/body.hlml.
15. LeBel M (1988). Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy, 8(1): 3-33.
16. Lubasch A, Keller I, Borner K, Koeppe P and Lode H (2000). Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother., 44(10): 2600-2603. (Pubitemid 30737669)
17. Khan MK and Khan MF (2005). Extraction and separation of ciprofloxacin by HPLC from human plasma. Intl. Chem. Med. J. 2(2): 267-270.
18. Nightinagle CH, Grant EM and Quintiliani R (2000). Pharmacodynamics and Pharmacokinetics of levofloxacin. Chemotherapy, 46(Suppl.l): 6-14.
19. Nouws JFM, Mevius DJ, Vree TB, Baars AM and Laurensen J (1988). Pharmacokinetics, renal clearance and metabolism of Ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Quart., 10: 156-163.
20. Owens RC, Patel KB, Banevicius MA, Quintiliani R, Nightingale CH and Nicolau DP (1997). Oral Bioavailability and Pharmacokinetics of Ciprofloxacin in patients with Aids. Antimicrob. Agents Chemother., 41(7): 1508-15 11.
21. Rao GS, Ramesh S, Ahmad AH, Tripathi HC, Shrama LD and Maiik JK (2002). Disposition kinetics of enrofloxacin and ciprofloxacin following intravenous administration of enrofloxacin in goats. Small Ruminant Research, 44: 9-15. (Pubitemid 34452024)
22. Seth SD, Beotra A and Seth S (1995). Comparative bioavailability of two brands of 57 Ciprofloxacin. J. Assoc. Physicians India, 43(5): 327-330.
23. Thomas M and File JR (2001). Infection diseases treatment updates - Fluoroquinolones. Clin. Infect. Dis., 15: 726-735.
24. Zeiler HJ and Grohe K (1984). The in vitro and in vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol., 3: 339-343.